KOSDAQRetail & Consumer019660

Globon

₩1,295▼ 0.31%2026-11-18 close
Market Cap
₩18.1B
Turnover
₩4,615,978
Volume
3.6K
Shares out.
13.9M
PER
—
PBR
2.1×
EPS
-₩510
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist as fertilizer trading contracts expand

Globon's revenue rebounded sharply in Q3 2026, but operating losses have continued for five straight quarters from Q3 2025, so the sales recovery has not yet translated into a return to profit.

  1. 1

    Revenue fell to KRW 12.9 billion in 2025 after peaking at KRW 20.3 billion in 2023, declining for two consecutive years, and the company swung to an operating loss of KRW 4.83 billion.

  2. 2

    Q3 2026 revenue rose to KRW 7.13 billion, up 120.5% from the prior quarter, but the company still recorded an operating loss of KRW 719 million.

  3. 3

    Fertilizer trading contracts disclosed in 2026 include anhydrous ammonia worth KRW 3.8 billion in late August and phosphoric and sulfuric acid worth KRW 2.67 billion in October, and whether these shift the revenue mix alongside the cosmetics business is the key point to watch.

  4. 4

    The debt-to-equity ratio rose from 20.2% in 2024 to 112.7% in 2025, operating cash outflow widened to KRW 3.98 billion, and the company has also disclosed convertible bond issuance and a collateral provision.

  5. 5

    The next periodic report is the 2026 annual report, and the next checkpoints are the direction of full-year 2026 operating results and the company's funding structure.

02

Business structure

Globon was founded in 1986 and listed on KOSDAQ in 1992. Its core business is the manufacture and sale of cosmetics, including basic skincare, mask packs and cosmetic containers.

Its own brand RUE KWAVE targets women who favor Korean Wave culture in China, Southeast Asia and the Middle East, sold directly through its own online mall and e-commerce channels. The company also earns B2B OEM and ODM revenue by producing cosmetics and containers for other brands.

Recent disclosures, however, show that a large share of contracts is fertilizer trading. An anhydrous ammonia supply contract signed on August 24, 2026 was worth KRW 3.8 billion, equal to 28.7% of prior-year revenue.

A phosphoric and sulfuric acid sales contract with PHILIPPINE PHOSPHATE FERTILIZER CORPORATION signed on October 12, 2026 was worth KRW 2.67 billion, or 20.62% of 2025 revenue, and was reported as SPOT trading.

At the March 31, 2026 general shareholders meeting, an amendment adding healthcare and cloud businesses to the articles of incorporation was approved.

Company profiles differ on the main lines of business: one lists cosmetics sales, semiconductor equipment distribution and mobile phone distribution, while another centers on cosmetics manufacturing and sales.

Which of cosmetics or fertilizer trading is the larger revenue driver is not clear from the sources, so both need to be tracked.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.1B-₩700M−17.5%
2025Q4₩5.2B-₩3B−58.9%
2026Q1₩2.8B-₩800M−30.3%
2026Q2₩3.2B-₩700M−20.5%
2026Q3₩7.1B-₩700M−10.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩18.5B-₩4.1B-₩6.4B−22.1%−42.9%86.9%
2023₩20.3B-₩4B-₩4.5B−19.7%−42.7%27.2%
2024₩17.3B₩200M₩600M1.4%5.0%20.2%
2025₩12.9B-₩4.8B-₩5.8B−37.3%−53.3%112.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Globon's annual results weakened clearly after the 2023 peak. Revenue rose from KRW 18.5 billion in 2022 to KRW 20.3 billion in 2023, a 9.9% increase, but then fell to KRW 17.3 billion in 2024, down 14.7%, and to KRW 12.9 billion in 2025, down 25.3%, declining for two consecutive years.

Operating results moved from an operating loss of KRW 4.09 billion in 2022 and KRW 3.99 billion in 2023, where the loss narrowed, to an operating profit of KRW 244 million in 2024, a swing to profit.

In 2025 the company returned to an operating loss of KRW 4.83 billion, and the operating margin fell from 1.4% in 2024 to -37.3%.

The company attributed the 2025 swing to a downturn that cut sales in its manufacturing and distribution businesses and reduced gross profit, as reported after its February 13, 2026 disclosure.

Net income attributable to controlling shareholders moved from a profit of KRW 553 million in 2024 to a loss of KRW 5.76 billion in 2025, and the net loss including non-controlling interests was also KRW 5.76 billion that year. The balance sheet changed as well.

Total equity at the end of 2025 was KRW 10.8 billion, all attributable to controlling shareholders, while total liabilities were KRW 12.2 billion, lifting the debt-to-equity ratio to 112.7%. Operating cash flow was negative KRW 1.84 billion in 2024 and negative KRW 3.98 billion in 2025.

The quarterly pattern is more mixed. Revenue rose from KRW 4.15 billion in Q3 2025 to KRW 5.17 billion in Q4 2025, up 24.7% quarter on quarter, yet the operating loss widened to KRW 3.04 billion in that quarter, more than half of the full-year 2025 operating loss.

Revenue then fell 46.2% to KRW 2.78 billion in Q1 2026 before rising to KRW 3.23 billion in Q2 and KRW 7.13 billion in Q3, two consecutive quarterly gains. The operating loss narrowed to KRW 843 million in Q1 2026 and KRW 662 million in Q2, then widened again to KRW 719 million in Q3.

The net loss attributable to controlling shareholders was KRW 1.12 billion in Q3 2026, larger than KRW 589 million a year earlier. The sum of the net losses attributable to controlling shareholders over the last four quarters was KRW 6.93 billion.

05

Industry analysis

Globon's cosmetics business depends on the overseas expansion of K-beauty demand.

The company sells RUE KWAVE to customers who favor Korean Wave culture in China, Southeast Asia and the Middle East, and the revenue triggers in those markets are cited as Chinese hygiene approvals, the box-office and streaming success of Korean content, and influencer and celebrity marketing.

These factors are sensitive to regulation and content trends in specific countries. On the domestic side, the company itself cited a business downturn that reduced sales in its manufacturing and distribution operations as the cause of the 2025 deterioration. Fertilizer trading has a different profile.

The recent anhydrous ammonia and phosphoric and sulfuric acid contracts are recognized as revenue on a contract-by-contract basis, so quarterly revenue can swing depending on when contracts are booked.

The phosphoric and sulfuric acid contract was reported as SPOT trading, with no down payment or advance payment and payment by telegraphic transfer. How raw material and global price movements affect trading margins cannot be determined from the disclosures alone.

Compared with the KOSDAQ distribution sector aggregated by FnGuide, Globon stands out for being in operating loss territory. Assessing its position in the sector will require disclosures that separate its own-brand sales from its trading revenue.

06

Outlook

The company has not disclosed full-year revenue or profit targets that can be verified, so the outlook rests on confirmed disclosures. The most recent verifiable business activity is fertilizer trading.

An anhydrous ammonia supply contract worth KRW 3.8 billion was disclosed on August 24, 2026, followed by a phosphoric and sulfuric acid contract worth KRW 2.67 billion on October 12, 2026.

The original disclosure gave the contract period as October 12, 2026 to February 23, 2027, but reports on a corrective filing say the end date was changed to November 30, 2026, so the two dates conflict. On the funding side, the company disclosed convertible bond issuance.

Reports put the conversion price at KRW 2,860 with up to 1,468,531 shares convertible, a potential dilution rate of 10.53%. A collateral provision for a third party was also disclosed on July 15, 2026.

On the business side, shareholders approved on March 31, 2026 an amendment adding healthcare data platforms, non-face-to-face medical solutions and cloud computing to the business purposes. The timing and scale of any revenue from these areas are not disclosed.

In cosmetics, Q3 2026 revenue rose sharply from the prior quarter, but whether that recovery continues into Q4 is not yet known. The next checkpoints are the full-year 2026 preliminary results and the 2026 annual report.

07

Valuation

PER
—
PBR
2.1×
ROE
-59.8%
EPS
-₩510
BPS
₩631
Dividend per share
₩0

The financial structure, rather than the share price level, is the starting point for interpreting valuation. Because the net loss attributable to controlling shareholders has continued over the last four quarters, a price-to-earnings ratio cannot be calculated.

The price-to-book ratio is in the range where the stock trades at a premium to net assets, and this sits alongside a market capitalization that is larger than total equity of KRW 10.8 billion. Whether net assets can generate earnings is the basis for that premium.

The company was profitable in 2024, so a recovery in earnings capacity is one reading, but losses have continued since 2025 and the quarterly results have not yet confirmed that reading. The dividend yield is below the sector average.

Comparing with past multiple bands has limited meaning for the period when earnings swung from profit to loss. A useful factual comparison is to view the multiples and asset structure against those of companies in the KOSDAQ distribution sector together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Rebound in quarterly revenue

Q3 2026 revenue reached KRW 7.13 billion, up 120.5% from the prior quarter and 72.0% from a year earlier. It marks two straight quarters of growth and the highest revenue among the last five quarters on a reported basis. If the recovery continues, it could help absorb fixed costs.

Scale of fertilizer trading contracts

The anhydrous ammonia contract disclosed on August 24, 2026 was KRW 3.8 billion, or 28.7% of prior-year revenue. The October 12, 2026 phosphoric and sulfuric acid contract equaled 20.62% of 2025 revenue. Additional revenue sources outside cosmetics would broaden the revenue base.

Track record of a swing to profit

In 2024 the company swung to an operating profit of KRW 244 million and a net profit attributable to controlling shareholders of KRW 553 million. That shows earnings capacity has not disappeared despite the later losses.

If the sales decline and gross profit squeeze the company cited for 2025 reverse, a path to earnings recovery would open.

09

Bear factors

Five straight quarters of operating losses

Operating losses have continued for five straight quarters from Q3 2025 through Q3 2026. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 6.93 billion.

Even with higher revenue in Q3 2026, the operating loss widened to KRW 719 million from the prior quarter, and the net loss attributable to controlling shareholders reached KRW 1.12 billion, larger than a year earlier.

Deterioration in financial structure

The debt-to-equity ratio rose from 20.2% in 2024 to 112.7% in 2025. Total liabilities at the end of 2025 were KRW 12.2 billion, exceeding total equity of KRW 10.8 billion. Operating cash outflow widened to KRW 3.98 billion, which could increase reliance on external financing.

Disclosure delays and corrections

A delay in submitting the audit report was disclosed on March 23, 2026, and at the March 31 shareholders meeting the 2025 separate financial statements were not put to a vote because the external audit was incomplete. Reports also cite four corrected filings over the past 18 months. Outside directors make up two of six board members, or 33.3%.

10

Risk factors

Financial capacity

Liabilities exceed total equity while operating cash flow is negative. Operating cash flow was negative KRW 3.98 billion in 2025. If losses continue, reliance on external funding for working capital could persist. The trend in the debt-to-equity ratio is a point to recheck in the next periodic report.

Dilution and contingent liabilities

Reports put the potential dilution from the convertible bonds at 10.53%, with a conversion price of KRW 2,860 and up to 1,468,531 shares. A collateral provision for a third party was disclosed on July 15, 2026. If the secured obligations are not met, it could become a burden, so the disclosures need to be tracked.

Shifts in business structure

Fertilizer trading contracts are often booked as single deals, which can cause large swings in quarterly revenue. The March 2026 amendment added healthcare and cloud businesses, but the timing of any revenue contribution is not disclosed.

If it remains unclear whether cosmetics or trading is the core business, evaluating the company will stay difficult.

11

What to watch next

  1. November 30, 2026 (per corrective-filing reports) · February 23, 2027 (per original disclosure)

    End date of the phosphoric and sulfuric acid supply contract with PHILIPPINE PHOSPHATE FERTILIZER CORPORATION. Reports conflict on the date, so the corrective filing itself should be checked. Payment collection and contract completion will indicate how the revenue is reflected in Q4.

  2. Around mid-February 2027 (based on the February 13, 2026 precedent)

    Full-year 2026 preliminary results. They will show the scale of the Q4 2026 operating loss and the full-year revenue trend, indicating whether the Q3 revenue recovery carried through the year.

  3. End of March 2027 (annual report filing deadline)

    The 2026 annual report, which will confirm full-year operating results, the debt-to-equity ratio, operating cash flow and the external audit opinion. It is also a point to check whether the delays seen with the 2025 statements recur.

12

Overall view

Globon's core business is cosmetics, but a large share of its recent disclosures concerns fertilizer trading contracts.

On a reported basis, revenue peaked at KRW 20.3 billion in 2023 and then declined for two consecutive years, and in 2025 the company swung to an operating loss of KRW 4.83 billion and a net loss attributable to controlling shareholders of KRW 5.76 billion.

Q3 2026 revenue rose to KRW 7.13 billion, two straight quarterly gains, but the operating loss of KRW 719 million extended a run of five consecutive quarterly losses. The debt-to-equity ratio rose to 112.7% and operating cash outflow widened, and convertible bond issuance and a collateral provision were disclosed.

Corrections to filings and a delay in the audit process in 2026 are also facts to weigh. Bullish factors include the revenue rebound, the expansion of fertilizer trading contracts and the 2024 swing to profit.

Bearish factors include consecutive losses, rising liabilities, dilution and contingent liabilities, and disclosure delays. The next checkpoints are the full-year 2026 preliminary results, the end and payment of the Philippine contract, and the operating results and cash flow in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. k5.co.kr
  4. investing-for-everyone.com
  5. thinkpool.com
  6. news.nate.com
  7. meerae.ai
  8. news.nate.com
  9. digitaltoday.co.kr
  10. stockcatcher.co.kr
  11. m.news.nate.com
  12. dailyan.com
  13. vegannews.co.kr
  14. m.news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. lifeandstyle.expansion.mx
  18. boletines.guanajuato.gob.mx

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis